Turning Point Brands Stock Rises Amid Positive Market Trends
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 04 2026
0mins
Should l Buy TPB?
Source: Benzinga
Turning Point Brands Inc. shares rose by 9.97% as the stock crossed above its 5-day SMA, reflecting a positive shift in market sentiment.
Despite recent FDA approval delays impacting investor confidence, the company's nicotine pouch segment has shown remarkable growth, achieving a 266% year-over-year increase in revenue last quarter. This growth, alongside a strong partnership with FRE Nicotine Pouches, which enhances brand visibility across major sports properties, is expected to drive future sales and market penetration.
The implications of this growth are significant, as Turning Point Brands continues to solidify its position in the premium nicotine market. Investors may view the current price movement as a potential buying opportunity, especially if they believe that the FDA concerns are temporary and that the company's revenue streams remain stable.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TPB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TPB
Wall Street analysts forecast TPB stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 81.830
Low
110.00
Averages
116.67
High
120.00
Current: 81.830
Low
110.00
Averages
116.67
High
120.00
About TPB
Turning Point Brands, Inc. is a manufacturer, marketer and distributor of branded consumer products. It sells a range of products to adult consumers, consisting of staple products under the brands Zig-Zag and Stoker’s. Its segments include Zig-Zag Products (Zig-Zag) and Stoker’s Products (Stoker’s). Zig-Zag principally markets and distributes rolling papers, tubes, and related products; finished cigars and make-your-own cigar wraps, and other accessories. It introduced Zig-Zag ‘Rillo-sized wraps, which are similar in size to cigarillos, a type of machine-made cigars. Stoker’s manufactures and markets moist snuff tobacco (MST) and contract for and market FRE, its modern oral product and contract for and market loose-leaf chewing tobacco products. Its products are available in approximately 200,000 in the United States retail locations which, with the addition of retail stores in Canada, brings its total North American retail presence to an estimated 220,000 points of distribution.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Turning Point Brands Partners with TKO Group for Marketing Deal
- Stock Surge: Turning Point Brands' stock soared over 10% on the day following the announcement of a multi-year marketing partnership with TKO Group, indicating strong shareholder approval and potential for enhanced market performance.
- Partner Background: TKO Group, owner of major sports entertainment assets like UFC and WWE, will promote Turning Point's FRE nicotine pouches across six of its brands, significantly increasing Turning Point's reach in the adult consumer market.
- Marketing Strategy: The partnership involves marketing FRE through what TKO describes as 'custom integrations and experiences,' a strategy likely to attract more adult consumers and boost sales and brand awareness.
- Missing Major Brand: Notably absent from TKO's announcement was WWE, the largest revenue source for TKO, suggesting that Turning Point may be exploring a separate marketing deal with TKO to further enhance its market presence.
See More
FRE Partners with TKO for Multi-Year Collaboration
- Partnership Formation: TKO Group Holdings has established a multi-year partnership with FRE Nicotine Pouches, making FRE the official partner across six TKO properties including UFC, Zuffa Boxing, and PBR, which is expected to significantly enhance brand visibility and market penetration.
- Target Audience Reach: With over 90% of UFC's audience being adults, FRE is leveraging this platform for responsible marketing of adult consumer products, which is anticipated to attract more existing nicotine users and enhance brand loyalty.
- Innovative Marketing Activities: FRE will conduct exclusive fan activations and custom content at venues like the UFC Octagon and Zuffa Boxing ring, aiming to boost user engagement through on-site experiences, thereby driving sales growth and brand recognition.
- Product Advantages Highlighted: FRE's nicotine pouches offer a range of strengths from 3-15mg and feature pre-primed moisture technology, catering to diverse consumer needs, which is expected to further solidify its leadership position in the premium nicotine product market.
See More
Turning Point Brands Stock Falls 15.5% Due to FDA Approval Delays
- Significant Stock Decline: Turning Point Brands' stock fell 15.5% this week, currently priced at $72.16 with a market cap of $1.4 billion, reflecting market concerns over FDA approval delays that could impact future revenue growth.
- Nicotine Pouch Business Growth: Despite facing FDA approval delays, Turning Point Brands' nicotine pouch segment achieved a remarkable 266% year-over-year growth last quarter, generating $41.3 million in revenue, which constitutes 34% of total company revenues, indicating strong market potential.
- Market Reaction Analysis: The FDA's cautious stance on nicotine pouch approvals has led investors to worry about the company's growth prospects, resulting in a 50% decline from its peak stock price, which may affect the company's financing capabilities and market confidence.
- Investment Opportunity Assessment: Despite short-term challenges, Turning Point Brands' stable revenue streams could still make it attractive in the long run; if investors believe the FDA concerns are merely temporary, the current stock price may present a buying opportunity.
See More
Turning Point Brands Shares Plunge 50% Amid FDA Concerns
- FDA Approval Delays: The FDA's slow approval process for new nicotine pouch types due to safety concerns for children has led to a 15.5% drop in Turning Point Brands' stock this week, with shares down 50% from their highs, significantly impacting market confidence in the company.
- Slowing Revenue Growth: Despite the Fre brand's nicotine pouch revenue growing 266% year-over-year to $41.3 million, accounting for 34% of total company revenues, the FDA's delays could hinder future revenue expectations, with guidance calling for net revenue of $180 million to $190 million for the category by 2026.
- Market Reaction: Turning Point Brands currently has a market cap of $1.3 billion, and while it maintains steady revenue from traditional products like rolling papers and chewing tobacco, investor reactions to the FDA's negative news have caused further declines in stock price.
- Investor Confidence Shaken: Following disappointing earnings reports, Turning Point Brands was not included in The Motley Fool's list of the 10 best stocks to buy, reflecting skepticism about its future growth potential and potentially affecting investor purchasing decisions.
See More
Tobacco Stocks Plummet Amid FDA Approval Concerns
- Regulatory Approval Delays: A Reuters report indicates that FDA scientists are hesitant to authorize oral nicotine products, leading to a sell-off among tobacco investors, with Turning Point Brands' stock plummeting over 14% in a single trading session, reflecting market concerns over new product introductions.
- Child Health Risks: The FDA scientists express worries about the potential risks these nicotine products pose to new users, particularly children, making it increasingly difficult for such products to gain approval and further impacting Turning Point's market outlook.
- Product Line Obstacles: Turning Point's applications for new versions of its Stoker's chewing tobacco and the Fre nicotine pouch products are currently in regulatory limbo, and continued delays from the FDA could severely hinder the company's product launches and revenue growth.
- Bleak Industry Outlook: Due to regulatory challenges, Turning Point and other tobacco companies may face a tough period ahead, with diminished investor confidence in their future growth, prompting a cautious approach to investments in this sector.
See More
FDA Concerns Over Nicotine Pouches Impact Tobacco Stocks
- FDA Regulatory Hurdles: FDA scientists express significant concerns regarding the approval of oral nicotine products like pouches, leading to a sharp sell-off among tobacco stock investors on Wednesday, with Turning Point Brands (TPB) plummeting over 14%, highlighting the direct impact of regulatory uncertainty on market confidence.
- Severe Market Reaction: The FDA's apprehensions about the potential risks of nicotine pouches, particularly concerning children, have shaken investor confidence in the tobacco sector, placing greater pressure on Turning Point and other tobacco firms, which may hinder future product launches.
- Product Line Delays: Turning Point's new products, including the classic Stoker's line and the Fre nicotine pouch, are currently in the regulatory pipeline; however, delays in FDA reviews could lead to uncertainty in their market introduction, adversely affecting the company's revenue growth and competitive position.
- Cautious Investor Sentiment: Given the unclear stance of the FDA, analysts advise a cautious approach towards Turning Point and its peers, suggesting that investors consider potential regulatory risks before making investment decisions, reflecting broader concerns about the future of the tobacco industry.
See More
Turning Point Brands Partners with TKO Group for Marketing Deal
- Stock Surge: Turning Point Brands' stock soared over 10% on the day following the announcement of a multi-year marketing partnership with TKO Group, indicating strong shareholder approval and potential for enhanced market performance.
- Partner Background: TKO Group, owner of major sports entertainment assets like UFC and WWE, will promote Turning Point's FRE nicotine pouches across six of its brands, significantly increasing Turning Point's reach in the adult consumer market.
- Marketing Strategy: The partnership involves marketing FRE through what TKO describes as 'custom integrations and experiences,' a strategy likely to attract more adult consumers and boost sales and brand awareness.
- Missing Major Brand: Notably absent from TKO's announcement was WWE, the largest revenue source for TKO, suggesting that Turning Point may be exploring a separate marketing deal with TKO to further enhance its market presence.
See More
FRE Partners with TKO for Multi-Year Collaboration
- Partnership Formation: TKO Group Holdings has established a multi-year partnership with FRE Nicotine Pouches, making FRE the official partner across six TKO properties including UFC, Zuffa Boxing, and PBR, which is expected to significantly enhance brand visibility and market penetration.
- Target Audience Reach: With over 90% of UFC's audience being adults, FRE is leveraging this platform for responsible marketing of adult consumer products, which is anticipated to attract more existing nicotine users and enhance brand loyalty.
- Innovative Marketing Activities: FRE will conduct exclusive fan activations and custom content at venues like the UFC Octagon and Zuffa Boxing ring, aiming to boost user engagement through on-site experiences, thereby driving sales growth and brand recognition.
- Product Advantages Highlighted: FRE's nicotine pouches offer a range of strengths from 3-15mg and feature pre-primed moisture technology, catering to diverse consumer needs, which is expected to further solidify its leadership position in the premium nicotine product market.
See More
Turning Point Brands Stock Falls 15.5% Due to FDA Approval Delays
- Significant Stock Decline: Turning Point Brands' stock fell 15.5% this week, currently priced at $72.16 with a market cap of $1.4 billion, reflecting market concerns over FDA approval delays that could impact future revenue growth.
- Nicotine Pouch Business Growth: Despite facing FDA approval delays, Turning Point Brands' nicotine pouch segment achieved a remarkable 266% year-over-year growth last quarter, generating $41.3 million in revenue, which constitutes 34% of total company revenues, indicating strong market potential.
- Market Reaction Analysis: The FDA's cautious stance on nicotine pouch approvals has led investors to worry about the company's growth prospects, resulting in a 50% decline from its peak stock price, which may affect the company's financing capabilities and market confidence.
- Investment Opportunity Assessment: Despite short-term challenges, Turning Point Brands' stable revenue streams could still make it attractive in the long run; if investors believe the FDA concerns are merely temporary, the current stock price may present a buying opportunity.
See More
Turning Point Brands Shares Plunge 50% Amid FDA Concerns
- FDA Approval Delays: The FDA's slow approval process for new nicotine pouch types due to safety concerns for children has led to a 15.5% drop in Turning Point Brands' stock this week, with shares down 50% from their highs, significantly impacting market confidence in the company.
- Slowing Revenue Growth: Despite the Fre brand's nicotine pouch revenue growing 266% year-over-year to $41.3 million, accounting for 34% of total company revenues, the FDA's delays could hinder future revenue expectations, with guidance calling for net revenue of $180 million to $190 million for the category by 2026.
- Market Reaction: Turning Point Brands currently has a market cap of $1.3 billion, and while it maintains steady revenue from traditional products like rolling papers and chewing tobacco, investor reactions to the FDA's negative news have caused further declines in stock price.
- Investor Confidence Shaken: Following disappointing earnings reports, Turning Point Brands was not included in The Motley Fool's list of the 10 best stocks to buy, reflecting skepticism about its future growth potential and potentially affecting investor purchasing decisions.
See More
Tobacco Stocks Plummet Amid FDA Approval Concerns
- Regulatory Approval Delays: A Reuters report indicates that FDA scientists are hesitant to authorize oral nicotine products, leading to a sell-off among tobacco investors, with Turning Point Brands' stock plummeting over 14% in a single trading session, reflecting market concerns over new product introductions.
- Child Health Risks: The FDA scientists express worries about the potential risks these nicotine products pose to new users, particularly children, making it increasingly difficult for such products to gain approval and further impacting Turning Point's market outlook.
- Product Line Obstacles: Turning Point's applications for new versions of its Stoker's chewing tobacco and the Fre nicotine pouch products are currently in regulatory limbo, and continued delays from the FDA could severely hinder the company's product launches and revenue growth.
- Bleak Industry Outlook: Due to regulatory challenges, Turning Point and other tobacco companies may face a tough period ahead, with diminished investor confidence in their future growth, prompting a cautious approach to investments in this sector.
See More
FDA Concerns Over Nicotine Pouches Impact Tobacco Stocks
- FDA Regulatory Hurdles: FDA scientists express significant concerns regarding the approval of oral nicotine products like pouches, leading to a sharp sell-off among tobacco stock investors on Wednesday, with Turning Point Brands (TPB) plummeting over 14%, highlighting the direct impact of regulatory uncertainty on market confidence.
- Severe Market Reaction: The FDA's apprehensions about the potential risks of nicotine pouches, particularly concerning children, have shaken investor confidence in the tobacco sector, placing greater pressure on Turning Point and other tobacco firms, which may hinder future product launches.
- Product Line Delays: Turning Point's new products, including the classic Stoker's line and the Fre nicotine pouch, are currently in the regulatory pipeline; however, delays in FDA reviews could lead to uncertainty in their market introduction, adversely affecting the company's revenue growth and competitive position.
- Cautious Investor Sentiment: Given the unclear stance of the FDA, analysts advise a cautious approach towards Turning Point and its peers, suggesting that investors consider potential regulatory risks before making investment decisions, reflecting broader concerns about the future of the tobacco industry.
See More
